Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Video

    GDPR Scrutiny & Big Data (Video)

    Alexander Roussanov discusses recent developments that make it difficult and complex for medical device and pharmaceutical companies to navigate the General Data Protection...
    European UnionPrivacy
    Arnold & Porter
    Arnold & Porter
  • Article

    CRISPR Regulatory Updates

    On December 15, 2023, Vertex announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion...
    GlobalFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
Article

FDA Approves Moderna’s MFLUSIVA (MRNA-1010) Seasonal Influenza Vaccine

Moderna's mRNA-1010 seasonal influenza vaccine has received FDA approval for adults 50 years and older, marking a significant milestone in mRNA vaccine technology. The approval follows a unanimous recommendation from FDA's advisory committee supporting the vaccine's benefit-risk profile across both middle-aged and senior adult populations.
GlobalFood, Drugs, Healthcare, Life Sciences
Goodwin Procter LLP
Goodwin Procter LLP
  • Article

    Takeda And Innovent Biologics Enter Collaboration Agreement On IBI343 And IBI363 Cancer Drugs

    Last week, Takeda announced that it has entered into a worldwide license and collaboration agreement (outside of Greater China) with Innovent Biologics for the development, manufacture, and commercialization...
    GlobalFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    US Policy Is Disrupting The Global Pharmaceutical Industry

    As recent US drug-pricing policy proposals prompt pharmaceutical companies to disclose European price benchmarks, questions are emerging around how these measures may influence market strategy.
    GlobalFood, Drugs, Healthcare, Life Sciences
    McDermott Will & Schulte
    McDermott Will & Schulte
  • Article

    U.S. Senators Request President Obama To Further China's GMO Approvals

    Both the United States and China agreed during the JCCT to "further cooperation and discussions regarding import requirements related to food safety."
    GlobalFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Final Rule On Cannabis Rescheduling Could Publish In Fall 2024, Sklamberg Says

    Life Sciences & Healthcare Regulatory partner Howard Sklamberg was recently featured in the MarketWatch article, "These cannabis stocks have solid growth prospects ...
    United StatesCannabis & Hemp
    Arnold & Porter
    Arnold & Porter
  • Article

    Keeping Education Accessible And Ending COVID-19 Vaccine Mandates In Schools (Trump EO Tracker)

    The order establishes a federal policy that prohibits the use of discretionary federal funds to support or subsidize educational institutions that require COVID-19 vaccinations for in-person attendance.
    United StatesConsumer Protection
    Akin
    Akin
  • Article

    Toward A Therapy For COVID-19: The Science And Legal Considerations

    Researchers around the world are working at record speed to find the best ways to treat and prevent COVID-19. In this last episode of our four-part podcast series, we discuss the science
    United StatesCoronavirus (COVID-19)
    Morrison Foerster
    Morrison Foerster
  • Podcast

    Toward A Vaccine For COVID-19: The Science And Legal Considerations (Podcast)

    In this third of a four-part podcast series, we discuss the science, regulatory framework, and commercial transactions considerations of a COVID-19 vaccine.
    United StatesCoronavirus (COVID-19)
    Morrison Foerster
    Morrison Foerster
  • Article

    Unpacking The Science And Legal Considerations Of COVID-19 Testing

    In this first of a four-part podcast series on the science, regulatory framework, commercial transactions, and privacy and data security ...
    United StatesCoronavirus (COVID-19)
    Morrison Foerster
    Morrison Foerster
  • Article

    2020 A-List Lawyers

    Christina Zhang and James Lu have been named A-List lawyers by China Business Law, which features 200 elite lawyers for China-related practice, including 100 lawyers working in PRC firms and 100 in foreign
    United StatesCorporate/Commercial Law
    Cooley LLP
    Cooley LLP
  • Article

    Aeglea BioTherapeutics Announces Acquisition Of Spyre Therapeutics And Concurrent PIPE Investment

    Cooley advised Aeglea BioTherapeutics, a clinical-stage biotechnology company, on its acquisition of Spyre Therapeutics and concurrent private investment.
    United StatesCorporate/Commercial Law
    Cooley LLP
    Cooley LLP
  • Article

    Dimensions Of Diversity: Closing The Gap: Jordan Fields On Tackling The Racial Wealth Divide

    On this episode of Dimensions of Diversity, host Lloyd Freeman is joined by Jordan Fields to discuss the racial wealth gap in America, focusing on taxation as a contributing factor.
    United StatesCorporate/Commercial Law
    Buchanan Ingersoll & Rooney
    Buchanan Ingersoll & Rooney
  • Article

    Finding A Way Through A Tight Deal Space

    Last year's contentious U.S. presidential election is often blamed for the slowdown in dealmaking activity in the life sciences space.
    United StatesCorporate/Commercial Law
    WilmerHale
    WilmerHale
  • Article

    Former Employee Of Biotech Firm Settles SEC Charges For Insider Trading

    The settlement is subject to court approval.
    United StatesCorporate/Commercial Law
    Hogan Lovells Cadwalader
    Hogan Lovells Cadwalader
  • Article

    Late-Stage Private Placements: A Life Sciences Sector Survey

    As privately held companies choose to remain private longer and defer their initial public offerings (IPOs), these companies are increasingly reliant on raising capital in successive private placements.
    United StatesCorporate/Commercial Law
    Morrison Foerster
    Morrison Foerster
  • Article

    Neogene Therapeutics To Sell To AstraZeneca

    Cooley advised Neogene Therapeutics, a global clinical-stage biotechnology company, ..
    United StatesCorporate/Commercial Law
    Cooley LLP
    Cooley LLP
  • Article

    Zoom, Slack Muscle Onto Top Silicon Valley List

    Many Silicon Valley companies are thriving amid the pandemic. The newly released Fenwick – Bloomberg Law SV 150 List, ranking the 150 largest public technology and life sciences companies
    United StatesCorporate/Commercial Law
    Fenwick
    Fenwick
  • Article

    But No One Goes To Jail For Insider Trading, Right? Wrong

    Schultz "Jason" Chan, former director of biostatistics at Akebia Therapeutics, Inc. (Nasdaq: AKBA), was sentenced to three years in prison following his conviction for insider trading.
    United StatesCriminal Law
    Foley Hoag LLP
    Foley Hoag LLP
  • Showing 341–360 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics